Quantcast

Latest Biologic Stories

2014-04-30 08:33:09

Proprietary "Smart Antibodies" Allow for Selective Activation in Cancerous Tissues SAN DIEGO, April 30, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,709,755, its first patent directed to methods of generating conditionally active antibodies. Conditionally active antibodies are...

2014-04-30 08:31:49

-- Conference Call Scheduled for Today, April 30, 2014 at 9 AM ET-- ROCKVILLE, Md., April 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, will host a conference call today to discuss in further detail the topline Phase II study results of Trimesta(TM) (oral estriol), which the Company is developing as a once-daily adjunctive...

2014-04-29 23:22:06

Gallus BioPharmaceuticals, a premier pure-play biologics contract development and manufacturing organization and Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT), jointly announced finalization of a multi-stage manufacturing services agreement. St. Louis, Missouri (PRWEB) April 29, 2014 Gallus BioPharmaceuticals, LLC(Gallus), a premier pure-play biologics contract development and manufacturing...

2014-04-29 08:36:38

BEIJING, April 29, 2014 /PRNewwire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release first quarter 2014 financial results on Tuesday, May 6, 2014 after the market closes. The Company's management will hold a conference call at 8:00 a.m. ET on Wednesday, May 7, 2014, which is 8:00 p.m., Beijing Time on May 7, 2014, to discuss...

2014-04-28 08:31:55

REDWOOD CITY, Calif., April 28, 2014 /PRNewswire/ -- Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Michael A. Fleming as Senior Vice President, Commercial Strategy. Mr. Fleming joins Coherus with more than 25 years of experience in strategic and operational leadership roles at preeminent biotech companies. "Michael is a vital addition to the Coherus team at this time," said Denny Lanfear, President and CEO of Coherus. "Our pipeline is now...

2014-04-28 08:31:24

DUBLIN, Apr. 28, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/85rshn/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual...

2014-04-23 12:29:37

New Entity YL Biologics to focus on clinical development and commercialization of Biosimilars for Japan MUMBAI and BALTIMORE, April 23, 2014 /PRNewswire/ -- Pharma Major, Lupin Limited (Lupin) announced today that it has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. (Yoshindo) to create a new entity, YL Biologics (YLB). YLB will be jointly managed by both partners and will be responsible for conducting...

2014-04-23 08:31:11

ROCKVILLE, Md., April 23, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive preclinical research findings for SYN-005, the Company's proprietary monoclonal antibody (mAb) combination therapy for treating Pertussis (whooping cough), in two non-human primate studies (n=15). In the second pertussis study in...

2014-04-22 12:27:06

Brazilian Public-Private Partnerships Drive Strong Growth in Biosimilars Pipeline, According to Findings from Decision Resources Group BURLINGTON, Mass., April 22, 2014 /PRNewswire/ -- Decision Resources Group finds that the number of publically disclosed biosimilar development projects has increased by more than 40 percent in the last 12 months. The majority of these development projects are yet to enter clinical development, but the 20 percent annual increase in the number of biosimilars in...

2014-04-22 04:21:26

Off-the shelf biologic medical device is now approved and poised for introduction in the EU for use in certain anterior cruciate ligament (ACL) knee surgeries SAN ANTONIO, Texas, April 22, 2014 /PRNewswire/ -- Aperion Biologics, Inc. was granted the CE Mark approval for its lead product, the Z-Lig(TM) ACLR device, to be used by surgeons in the European Union and other territories that accept the CE Mark. The Z-Lig(TM) is the first engineered biologic device for treatment of revision...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related